Form 4 for STLN Starling Oncology, Inc.
Accepted 2025-11-24 00:00:00 ET · period of report 2025-11-20 · accession 0001553350-25-000144 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2025-11-24 | 2025-11-20 | STLN | Pacala Mark L | Dir | A - Grant | $0.00 | +81.8K | 221.3K | +59% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-11-20 | A | A | 35,494 | $0.00 | 256,761 | D | — | — | (F2) Represents restricted stock units that were fully vested upon grant. |
| 2 | Common | Common Stock | 2025-11-20 | A | A | 46,296 | $0.00 | 221,267 | D | — | — | (F1) Represents restricted stock units that vest in full on Issuer's 2026 annual stockholder meeting date, subject to continued service with the Issuer through such vesting date. |